间充质干细胞对脓毒症器官功能障碍的免疫调节与治疗作用
该综述概述了脓毒症及其病理生理,重点总结间充质干细胞(MSC)及MSC来源分泌组在改善脓毒症诱导器官功能障碍方面的近期发现。脓毒症由感染期间失调的炎症反应引起,主要影响孕妇、新生儿和ICU患者;延迟治疗可因组织缺血缺氧导致不可逆器官衰竭和死亡,累及四或五个器官时死亡风险超过90%。抗生素虽是脓毒症一线治疗,但不足以控制疾病和预防后续器官衰竭。MSC具有免疫调节、抗炎、抗凋亡和抗菌特性,临床前研究中给予MSC与细菌负荷降低、促炎因子水平下降以及心、肾、肝、肺等重要器官功能改善相关。综述还讨论了适合MSC治疗的脓毒症候选人群及该领域最新临床发现。
要点
- 脓毒症由感染期间失调的炎症反应引起,主要影响孕妇、新生儿和ICU患者,延迟治疗可导致不可逆多器官衰竭和死亡。
- 脓毒症累及四或五个器官时,死亡风险被归因于超过90%。
- 抗生素是脓毒症一线治疗,但不足以控制疾病和预防后续器官衰竭。
- 临床前研究中,给予MSC与细菌负荷降低、促炎因子水平下降及心、肾、肝、肺功能改善相关。
- MSC的免疫调节、抗炎、抗凋亡和抗菌特性使其被视为有前景的治疗策略,综述还讨论了适合MSC治疗的脓毒症候选人群及最新临床发现。
适用人群与场景
- 脓毒症患者,尤其是孕妇、新生儿和重症监护病房患者。
- 综述讨论了适合MSC治疗的脓毒症候选人群。
红旗征与不能漏的情况
- 延迟治疗可因组织血供不足和氧减少导致各种器官不可逆衰竭,最终增加死亡率。
研究设计与关键结果
- 综述指出,脓毒症由感染期间失调的炎症反应引起,主要影响孕妇、新生儿和ICU患者。
- 脓毒症累及四或五个器官时,死亡风险被归因于超过90%。
- 抗生素是脓毒症一线治疗,但不足以控制疾病和预防后续器官衰竭。
- 临床前研究中,给予MSC与细菌负荷降低、促炎因子水平下降以及心、肾、肝、肺等重要器官功能改善相关。
- 综述总结了MSC及MSC来源分泌组在改善脓毒症诱导器官功能障碍方面的近期发现,并回顾了适合MSC治疗的脓毒症候选人群及最新临床发现。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 综述指出MSC具有免疫调节、抗炎、抗凋亡和抗菌特性,其应用被视为有前景的治疗策略。
- 临床前研究显示MSC给药与细菌负荷降低、促炎因子水平下降及心、肾、肝、肺功能改善相关。
- 综述讨论了适合MSC治疗的脓毒症候选人群及该领域最新临床发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is a life-threatening disorder that is caused by a dysregulated inflammatory response during an infection. The disease mostly affects pregnant women, newborns, and patients in intensive care units. Sepsis treatment is a significant part of a country's health budgets. Delay in the therapy causes irreversible failure of various organs due to the lack of blood supply and reduction of oxygen in the tissues and eventually increased mortality. The involvement of four or five organs by sepsis has been attributed to an increased risk of death to over 90%. Although antibiotics are at the first line of sepsis treatment, they do not possess enough potency to control the disease and prevent subsequent organ failure. The immunomodulatory, anti-inflammatory, anti-apoptotic, and anti-microbial properties of mesenchymal stem cells (MSCs) have been reported in various studies. Therefore, the application of MSCs has been considered a potentially promising therapeutic strategy. In preclinical studies, the administration of MSCs has been associated with reduced bacterial load and decreased levels of pro-inflammatory factors as well as the improved function of the different vital organs, including heart, kidney, liver, and lungs. The current study provides a brief review of sepsis and its pathophysiology, and then highlights recent findings in the therapeutic effects of MSCs and MSC-derived secretome in improving sepsis-induced organ dysfunction. Besides, eligible sepsis candidates for MSC-therapy and the latest clinical findings in these areas have been reviewed.
参考来源
- Khosrojerdi A, Soudi S, Hosseini AZ, et al. Immunomodulatory and Therapeutic Effects of Mesenchymal Stem Cells on Organ Dysfunction in Sepsis. Shock. 2021. PMID: 32826813. doi:10.1097/SHK.0000000000001644
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。